Everything below concerns thymosin alpha 1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The brief existence of an mRNA molecule begins with transcription, and ultimately ends in degradation. During its life, an mRNA molecule may also be processed, edited, and transported prior to translation. Eukaryotic mRNA molecules often require extensive processing and transport, while prokaryotic mRNA molecules do not. A molecule of eukaryotic mRNA and the proteins surrounding it are together called a messenger RNP.
The maximum life span of transgenic mice has been extended about 20% by overexpression of human catalase targeted to mitochondria A comparison of 7 non-primate mammals (mouse, hamster, rat, guinea-pig, rabbit, pig and cow) showed that the rate of mitochondrial superoxide and hydrogen peroxide production in heart and kidney were inversely correlated with maximum life span A study of 8 non-primate mammals showed an inverse correlation between maximum life span and oxidative damage to mtDNA (mitochondrial DNA) in heart & brain A study of several species of mammals and a bird (pigeon) indicated a linear relationship between oxidative damage to protein and maximum life span There is a direct correlation between DNA repair and maximum life span for mammalian species Drosophila (fruit-flies) bred for 15 generations by only using eggs that were laid toward the end of reproductive life achieved maximum life spans 30% greater than that of controls Overexpression of the enzyme which synthesizes glutathione in long-lived transgenic Drosophila (fruit-flies) extended maximum lifespan by nearly 50% A mutation in the age−1 gene of the nematode worm Caenorhabditis elegans increased mean life span 65% and maximum life span 110%. However, the degree of lifespan extension in relative terms by both the age-1 and daf-2 mutations is strongly dependent on ambient temperature, with ≈10% extension at 16 °C and 65% extension at 27 °C. Fat-specific Insulin Receptor KnockOut (FIRKO) mice have reduced fat mass, normal calorie intake and an increased maximum life span of 18%.
Beginning in 1973, Domino's Pizza offered a guarantee to customers their pizza would be delivered within 30 minutes of placing an order or they would receive the pizza free. This guarantee was changed to $3 off in 1987. In 1992, the company settled a lawsuit brought by the family of an Indiana woman who had been killed by a speeding Domino's delivery driver, paying the family $2.8 million. In another lawsuit in 1993, a woman who was injured when a Domino's delivery driver ran a red light and collided with her vehicle was awarded nearly $80 million by a jury, but accepted a payout of $15 million. The half-hour guarantee was dropped that year because of the "public perception of reckless driving and irresponsibility", according to then-CEO Tom Monaghan. In December 2007, Domino's introduced a new slogan, "You Got 30 Minutes", alluding to the earlier pledge, but stopping short of promising delivery in half an hour. The company continues to honor the 30-minute guarantee for orders placed in its stores located in Colombia, Vietnam, Mexico, China, and India. The 30-minute guarantee is subject to the terms and conditions applied in the respective country.
== Promotion == In March 2006, it was announced that "Come What May," would be released on July 18, 2006. However, the release date for the album was pushed back until August 22. Because of the delay, Stone Sour released a music video for the track "Reborn", which had footage of the band working on the album in the studio. The album's cover artwork was released online on May 20, 2006. Shortly after, it was confirmed by a representative from the band's record label, Roadrunner, that the release date had been brought forward, and the official release date would be August 1, 2006. On July 31, 2006, the day before its release the album was made available online for streaming in its entirety through AOL. On May 22, 2006, the first single from the album, "30/30-150", was made available online as a free MP3 download. A music video for the single was shot with director P.R. Brown in Los Angeles and received a premier on MTV's Headbangers Ball on June 3, 2006. Prior to the release of the second single from the album, "Through Glass", radio stations throughout the US showed high support for the song. A music video for the single was shot with director Tony Petrossian and was released online on June 9, 2006, through Yahoo!. The third single from the album, "Sillyworld", began receiving radio airplay in November 2006. A music video for the single was shot in January 2007 and was released online on March 8, 2007. The fourth single from the album, "Made of Scars", had a music video which was recorded live on April 7, 2007, and was posted online on June 5, 2007.
An example is copper-64, which has 29 protons, and 35 neutrons, which decays with a half-life of 12.7004(13) hours. This isotope has one unpaired proton and one unpaired neutron, so either the proton or the neutron can decay to the other particle, which has opposite isospin. This particular nuclide (though not all nuclides in this situation) is more likely to decay through beta plus decay (61.52(26)%) than through electron capture (38.48(26)%). The excited energy states resulting from these decays which fail to end in a ground energy state, also produce later internal conversion and gamma decay in almost 0.5% of the time.
Sources: en.wikipedia.org
(CH2CH2)O + PCl3 → Cl–CH2CH2–OPCl2 2 (CH2CH2)O + PCl3 → (Cl–CH2CH2–O)2PCl 3 (CH2CH2)O + PCl3 → Cl–CH2CH2–O)3P The reaction product of ethylene oxide with acyl chlorides in the presence of sodium iodide is a complex iodoethyl ester:
Allosteric activation by glucose-6-phosphate, which acts as an effector, stimulates glycogen synthase, and glucose-6-phosphate may inhibit the phosphorylation of glycogen synthase by cyclic AMP-stimulated protein kinase.
Dingane's army then attacked and massacred a group of 250 Voortrekker men, women and children camped nearby. The site of this massacre is today called Weenen, (Dutch for "to weep"). The remaining Voortrekkers elected a new leader, Andries Pretorius, who led a successful defence of the Voortrekker position from the Zulu forces and Dingane at the Battle of Blood River on 16 December 1838, when 15,000 Zulu impis (warriors) attacked a group of 470 Voortrekker settlers led by Pretorius.
== Growth of the bacterial culture == Plasmids are almost always purified from liquid bacteria cultures, usually E. coli, which have been transformed and isolated. Virtually all plasmid vectors in common use encode one or more antibiotic resistance genes as a selectable marker, for example a gene encoding ampicillin or kanamycin resistance, which allows bacteria that have been successfully transformed to multiply uninhibited. Bacteria that have not taken up the plasmid vector are assumed to lack the resistance gene, and thus only colonies representing successful transformations are expected to grow. Bacteria are grown under favourable conditions.
Sources: en.wikipedia.org
=== Colorado === On May 17, 2024, Colorado Governor Jared Polis signed the Colorado AI Act (CAIA) into law. The CAIA establishes requirements for deployers and developers of high-risk AI systems, including transparency obligations and risk assessments, to prevent algorithmic discrimination against Colorado residents. It is the first comprehensive, state-level law that regulates high-risk AI systems in the United States. The law was unpopular among pro-business advocates. An attempt to amend the regulation failed, but its implementation was delayed from the original February 1, 2026 start date to an expected June 1, 2026 start. Jared Polis has created a committee to investigate its implementation. Brianna Titone, the bill's sponsor, criticized the commission for being full of industry representatives without representation from consumers across the state. On May 14, 2026, Polis signed into law SB 26-189, which repealed and replaced CAIA. The replacement law eliminated the focus on high-risk systems; instead, it requires companies that deploy AI for decision-making related to certain topics (like employment or housing) to inform individuals that AI is being used.
Omics.org Archived 2014-01-02 at the Wayback Machine Omics terms and concepts home page. Probably the first omics web page created. List of omics Archived 2015-07-09 at the Wayback Machine, including references/origins. Maintained by the (CHI) Cambridge Health Institute.
The grant proposal was turned over for peer review, and one of the reviewers was Steven Jones of Brigham Young University. Jones had worked for some time on muon-catalyzed fusion, a known method of inducing nuclear fusion without high temperatures, and had written an article on the topic entitled "Cold nuclear fusion" that had been published in Scientific American in July 1987. Fleischmann and Pons and co-workers met with Jones and co-workers on occasion in Utah to share research and techniques. During this time, Fleischmann and Pons described their experiments as generating considerable "excess energy", in the sense that it could not be explained by chemical reactions alone. They felt that such a discovery could bear significant commercial value and would be entitled to patent protection. Jones, however, was measuring neutron flux, which was not of commercial interest. To avoid future problems, the teams appeared to agree to publish their results simultaneously, though their accounts of their 6 March meeting differ.
The Japan Self-Defense Forces use two types of combat rations, Type I combat ration (Japanese: 戦闘糧食 I型) and Type II combat ration (Japanese: 戦闘糧食 II型). The older Type I ration consists almost entirely of canned foods weighing a total of 780 g per meal; a normal three-day ration has up to 36 cans weighing more than 7 kilograms. Eight menus are available, based around a 400 g can of rice and 2–3 smaller supplemental cans. Typical contents include: rice (white rice, sekihan, mixed rice with vegetables, or rice with mushrooms), a main meal can (chicken and vegetables, beef with vegetables, fish and vegetables, or hamburger patties), pickled vegetables (takuan or red cabbage) and sometimes a supplemental can (tuna in soy or beef in soy). In the latest type I combat rations, cans have been replaced by retort pouches. The newer, lighter Type II ration was originally intended to replace the Type I and consists of pre-cooked, ready-to-eat items in plastic-foil laminate retort pouches, packed in turn inside a drab green polyethylene meal bag. Each meal consists of two 200 g pouches of rice (white rice, rice with red beans, mixed rice with meat and vegetables, fried rice, curried rice pilaf, rice with green peas, or rice with wild herbs) plus 2–3 supplementary pouches. Main meal pouches contain: hamburger patties, frankfurters, beef curry, grilled chicken, Chinese meatballs, Sweet and Sour pork, grilled salmon, yakitori chicken, mackerel in ginger sauce, chicken and vegetables, and tuna.
=== Modern and contemporary === In the modern period, secularization and scientific progress shifted the focus from religious theories to naturalistic explanations, particularly starting in the late 17th century with the Age of Enlightenment. Voltaire (1694–1778), Jean-Jacques Rousseau (1712–1778), Denis Diderot (1713–1784), Adam Smith (1723–1790), and François-Jean de Chastellux (1734–1788) rejected a religious focus on otherworldly well-being, emphasizing instead the pursuit of earthly happiness through reason, empirical inquiry, and social progress.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
Aliquots are typically frozen well below zero Celsius and thawed only once, since repeated cycles promote aggregation and loss. Dilution into a neutral buffer limits degradation during short working periods, and prolonged storage at room temperature is avoided.